Deshmukh Parikshit, Kulkarni Guarav, Barzman Drew
Dr. Deshmukh is a resident with the Division of Psychiatry, University Hospitals Case Medical Center, Cleveland, Ohio.
Psychiatry (Edgmont). 2010 Feb;7(2):32-40.
Objective. While there has been a great deal of speculation by clinical researchers over the last three decades on effective and safe methods for the pharmacological management of aggression in children and adolescents, it is only in the last decade that there have been well-designed studies available to address this issue. Medication is commonly used to control aggression in children and adolescents in inpatient units. Also, there exists a need for evidence-based guidelines for the use of these different pharmacological agents for managing pediatric aggression on inpatient units. The aims of this article are to provide a systemic review and to provide treatment guidelines based on these limited but currently available studies.Methods. The articles reviewed in this study were obtained through a PubMed search using the key words 'children,' 'adolescents,' 'aggression,' 'inpatient,' 'ziprasidone,' 'lithium,' and 'risperidone.' A total of 499 studies were generated. Only studies focusing on pharmacological management of inpatient pediatric aggression with mean duration less than six weeks and published during January 1980 to August 2009 were included. Only English articles were considered. A total of 13 studies met these criteria, which were included in the review without any further statistical analysis. Recommendations are made on this available evidenced-based literature.Results. There is some evidence for the standing use of oral lithium, haloperidol, olanzapine, and risperidone for aggression related to specific psychiatric diagnoses. Intramuscular ziprasidone and olanzapine administered as needed were found to be effective for the rapid management of moderate to severe aggression. Oral or intramuscular diphenhydramine administered as needed was found to be useful for managing mild aggression due to a placebo effect.Conclusions. Studies are available on managing aggression in children and adolescents in inpatient treatment settings but are limited. Further studies on the use of various psychotropic medications are needed in order to develop comprehensive guidelines for the safe and effective pharmacological management of child and adolescent inpatient aggression.
目的。在过去三十年里,临床研究人员对儿童和青少年攻击行为的有效且安全的药物管理方法进行了大量推测,但直到最近十年才有精心设计的研究来解决这一问题。药物治疗常用于控制住院儿童和青少年的攻击行为。此外,对于在住院部使用这些不同药物治疗儿童攻击行为,需要有基于证据的指南。本文的目的是进行系统综述,并根据这些有限但目前可得的研究提供治疗指南。
方法。本研究中所综述的文章通过在PubMed上搜索关键词“儿童”“青少年”“攻击行为”“住院患者”“齐拉西酮”“锂盐”和“利培酮”获得。共检索到499项研究。仅纳入了关注住院儿童攻击行为药物管理、平均持续时间少于六周且发表于1980年1月至2009年8月期间的研究。仅考虑英文文章。共有13项研究符合这些标准,直接纳入综述,未进行进一步的统计分析。基于现有循证文献给出建议。
结果。有证据表明口服锂盐、氟哌啶醇、奥氮平和利培酮持续用于与特定精神疾病诊断相关的攻击行为有效。按需给予肌内注射齐拉西酮和奥氮平被发现对快速控制中度至重度攻击行为有效。按需给予口服或肌内注射苯海拉明因安慰剂效应被发现对控制轻度攻击行为有用。
结论。关于住院治疗环境中儿童和青少年攻击行为管理的研究是存在的,但很有限。需要对各种精神药物的使用进行进一步研究,以便制定全面的指南,用于安全有效地药物管理儿童和青少年住院患者的攻击行为。